Quoin Pharmaceuticals, Ltd. (QNRX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
Analysts estimate Earnings Per Share (EPS) of $-72.80 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1,911.50 vs est $-72.80 (missed -2525.7%). 2025: actual $-14,796.30 vs est $-20.16 (missed -73312.6%). Analyst accuracy: 2%.
QNRX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Quoin Pharmaceuticals, Ltd. in the past 3 months
EPS Estimates — QNRX
2%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1,911.50
vs Est –$72.80
▼ 96.2% off
2025
Actual –$14,796.30
vs Est –$20.16
▼ 99.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — QNRX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
